FDA approves Rasonque after 13.2-month survival result in metastatic pancreatic cancer

The U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib) on 26 August 2026 for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy, giving UAE oncology teams a new second-line treatment to track before local registration.

The immediate value is for medical directors, CFOs and payer teams. The clinical signal is unusually concrete: in the FDA-cited RASolute 302 trial of 500 adults, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy. For Dubai providers regulated by the Dubai Health Authority (DHA), the next operational question is when the drug appears through UAE channels and how quickly tumour testing and prior-authorisation rules can be updated.

What the FDA approved

Daraxonrasib is an oral RAS GTPase inhibitor from Revolution Medicines. The FDA approval covers adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy, according to the FDA approval notice.

The recommended FDA dose is 300 mg orally once daily until disease progression or unacceptable toxicity. The FDA said median progression-free survival was 7.2 months with daraxonrasib and 3.6 months with standard chemotherapy. Objective response rate was 30% versus 11%. The warning profile includes dermatologic and soft tissue toxicity, stomatitis, diarrhoea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo-fetal toxicity.

“This drug showed unprecedented results in an area of high unmet need,” said Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence.

Gulf News reported the FDA decision as a first-of-its-kind pill targeting the RAS protein, which is implicated in more than 90% of pancreatic cancer cases. The FDA press release puts the U.S. pancreatic cancer burden at about 67,000 new cases a year, with pancreatic adenocarcinoma accounting for 90% to 95% of those cases.

What UAE operators should do now

A U.S. FDA approval does not make the product automatically available in Dubai, Abu Dhabi or the northern emirates. The UAE route runs through the Emirates Drug Establishment (EDE) for marketing authorisation. EDE lists a 45-working-day service duration for marketing authorisation of a drug or biopharmaceutical product, with an application fee of AED 100 and a marketing authorisation fee of AED 7,000 for conventional or biological products on its service page.

Dubai hospitals and oncology centres should prepare four files before the first patient request reaches the pharmacy committee:

• Eligibility: metastatic pancreatic adenocarcinoma, prior systemic therapy, or unsuitability for multiagent systemic therapy.
• Testing: local capability for RAS mutation documentation and pathology reporting before second-line treatment selection.
• Governance: formulary review, consent language, toxicity monitoring and serious adverse-event reporting.
• Payer evidence: FDA label, RASolute 302 efficacy data, line of therapy, expected treatment duration and alternatives tried.

For Abu Dhabi, the payer conversation will run through Department of Health Abu Dhabi (DOH) rules and plan-specific medical necessity criteria. For the northern emirates, providers should expect Ministry of Health and Prevention (MOHAP) facility oversight to matter for oncology service delivery while EDE handles product market access. Large payers such as Daman, Thiqa and Sukoon should be named in internal reimbursement work only where the patient’s policy, network and prior-authorisation pathway confirm they apply.

Pricing and patient access

The commercial issue is material. The Wall Street Journal reported a U.S. monthly price of $39,800, equal to about AED 146,200 at the dollar-dirham peg, before UAE distributor terms, VAT treatment, hospital mark-ups, infusion-centre costs for supporting care, diagnostics and monitoring. UAE clinics should not quote a patient price until the EDE registration status, local distributor terms and payer approval are visible.

For CFOs, the working model should separate the tablet cost from related oncology spend. A realistic access pack should include consultation fees, molecular pathology, baseline imaging, repeat imaging, liver and inflammatory markers where clinically required, adverse-event management and pharmacy handling. The UAE Open Healthcare Directory lists typical Dubai oncology consultation pricing at AED 600 to AED 1,500, but the medicine cost will dominate if the product is self-pay or outside the benefit schedule.

Patients should ask three questions before travelling or paying cash: whether the medicine is UAE-registered or accessed through a named legal route, whether their insurer has issued written pre-authorisation, and whether the treating oncologist has documented eligibility against the FDA-approved population. Operators should direct patients to licensed oncology providers rather than informal import channels.

The practical next step is to monitor EDE registration, pharmacy committee decisions and payer circulars, then update second-line pancreatic cancer pathways within 30 days of local availability. Patients and referring doctors can compare licensed oncology providers through the UAE Open Healthcare Directory.